Stock Abbreviation: Qianyuan Pharmaceutical
Stock Code: 300254
Shanxi Qianyuan Pharmaceutical Group Co., Ltd.
2026 Restricted Stock Incentive Plan
(Draft) Summary
August 2026
Statement
The Company and all directors guarantee that this incentive plan and its summary contain no false records, misleading statements, or major omissions, and assume individual and joint legal liability for their authenticity, accuracy, and completeness.
Special Notice
-
This incentive plan is formulated in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Administrative Measures for Equity Incentives of Listed Companies, the Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange, the Guidelines No. 1 for Self-Regulation of Listed Companies on the ChiNext Market—Business Handling, and other relevant laws, regulations, and normative documents, as well as the Articles of Association of Shanxi Qianyuan Pharmaceutical Group Co., Ltd.
-
The incentive tool adopted in this plan is restricted stock (Type I restricted stock). The source of the shares is the Company's A-share common stock issued to the incentive targets.
-
The total number of restricted shares to be granted under this plan shall not exceed 17.00 million shares, accounting for 6.61% of the Company's total share capital of 257.208563 million shares at the time of the announcement of this draft. Of this, 14.00 million shares will be granted for the first time, accounting for approximately 5.44% of the total share capital and 82.35% of the total equity granted. The reserved portion is 3.00 million shares, accounting for approximately 1.17% of the total share capital and 17.65% of the total equity granted.
As of the disclosure date of this announcement, after deducting the Type I restricted shares already repurchased and cancelled, the number of shares under the 2024 restricted stock incentive plan is 6.64 million, and the number of shares under the 2025 restricted stock incentive plan is 9.05 million. Including the 17.00 million shares under this plan, the total number of underlying shares involved in all historical and current incentive plans is 32.69 million, accounting for 12.71% of the total share capital at the time of the announcement.
The total number of underlying shares involved in all effective equity incentive plans does not exceed 20% of the Company's total share capital. Under this plan, 7.50 million shares are proposed to be granted to Chairman Huang Lequn, accounting for 2.92% of the total share capital; combined with shares granted in 2024, this totals 3.03%. As a core decision-maker, Mr. Huang Lequn's stability is vital to the Company's R&D strategy and governance. Based on his historical contributions and the irreplaceability of his role, the Company proposes granting him restricted shares exceeding 1% of the total share capital. Pursuant to Article 14 of the Administrative Measures for Equity Incentives of Listed Companies, this requires approval by a special resolution of the shareholders' meeting.
If the Company undergoes capital reserve capitalization, stock dividends, share splits or consolidations, or rights issues between the announcement of this draft and the registration of the restricted shares, the number of shares granted will be adjusted accordingly.
-
The grant price (including reserved) of the restricted shares is 6.27 yuan per share. If the Company undergoes capital reserve capitalization, stock dividends, share splits or consolidations, rights issues, or dividend distributions during the specified period, the grant price will be adjusted accordingly.
-
The total number of incentive targets for the initial grant is 49, including directors, senior management, and core technical and management personnel. Reserved incentive targets shall be determined by the Board of Directors within 12 months after the shareholders' meeting approves the plan.